Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002000732 | SCV002267736 | likely pathogenic | Glycine encephalopathy | 2023-07-09 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1482131). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLDC protein function. This missense change has been observed in individual(s) with glycine encephalopathy (PMID: 27362913). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 79 of the GLDC protein (p.Leu79Pro). |
Gene |
RCV004719217 | SCV005325903 | uncertain significance | not provided | 2023-07-24 | criteria provided, single submitter | clinical testing | Identified with a second GLDC variant on the opposite allele (in trans) in a patient with suspected nonketotic hyperglycinemia in published literature, although clinical details were not provided (Coughlin et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27362913) |